Aktis Oncology, Inc.

The Company classifies its commercial paper, corporate debt securities, and agency bonds as Level 2 assets under the fair value hierarchy, as these assets have been valued using quoted prices in active markets for similar securities.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Marketable securities As of June 30, 2026 and December 31, 2025, the Company s security portfolio consisted of 95 securities and 56 securities, respectively, related to marketable securities in debt securities available-for-sale, of which there were 88 securities and 10 securities in unrealized loss positions as of June 30, 2026 and December 31, 2025 , respectively.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Both common stockholders and Class A common stockholders are entitled to receive dividends, as may be declared by the Company s Board, if any.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Through June 30, 2026 , no dividends have been declared or paid.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Any shares underlying outstanding stock awards granted under the 2020 Plan that subsequently expire or are repurchased, forfeited, cancelled, or withheld will return to the 2026 Plan and be reserved and available for issuance.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

As the liquidation and dividend rights are identical for the Company's common stock and Class A common stock, the undistributed earnings are allocated on a proportionate basis and the resulting amount per share for the Company's common stock and Class A common stock was the same for the three and six months ended June 30, 2026.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

(NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the second quarter ended June 30, 2026.

SEC original ↗Aktis Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

“This was a quarter of strong execution for Aktis, focused on generating clinical data and building infrastructure to support our clinical pipeline,” said Matthew Roden, Ph.

SEC original ↗Aktis Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

We also expect to continue operationalizing our internal GMP facility as part of our comprehensive strategy to enable our own clinical supply for our pipeline.

SEC original ↗Aktis Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

• Corporate: o In-house Good Manufacturing Practices (GMP) facility expected to be operational in the second half of 2026 as part of the Company’s hybrid manufacturing strategy to expand capabilities and support clinical supply demand.

SEC original ↗Aktis Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.

SEC original ↗Aktis Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements.

SEC original ↗Aktis Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A, Risk Factors of this Quarterly Report on Form 10-Q.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Legal Proceedings 25 Item 1A.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Risks and uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, the outcome of clinical trials, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technologies, compliance with government regulations, ability to secure additional capital to fund operations, and potential delays associated with the Company s anticipated and planned trials.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Liquidity In accordance with Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties About an Entity s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company s ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued.

SEC original ↗Aktis Oncology, Inc. — 10-Q Quarterly report10-QAug 13, 2026